Publicaciones (386) Publicaciones de Alfredo Carrato Mena

2024

  1. Targeting cancer stem cell OXPHOS with tailored ruthenium complexes as a new anti-cancer strategy

    Journal of Experimental and Clinical Cancer Research, Vol. 43, Núm. 1

2023

  1. Discordant Humoral and T-Cell Response to mRNA SARS-CoV-2 Vaccine and the Risk of Breakthrough Infections in Women with Breast Cancer, Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors

    Cancers, Vol. 15, Núm. 7

  2. Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue

    Journal of Visualized Experiments, Vol. 2023, Núm. 195

  3. Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights

    European Urology, Vol. 84, Núm. 1, pp. 127-137

  4. Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases

    ESMO Open, Vol. 8, Núm. 2

  5. Physical Activity is Medicine

    JNCCN Journal of the National Comprehensive Cancer Network, Vol. 21, Núm. 12, pp. 1312-1314

2022

  1. A faecal microbiota signature with high specificity for pancreatic cancer

    Gut, Vol. 71, Núm. 7, pp. 1359-1372

  2. Adjuvant chemotherapy after curative D2 gastrectomy in Latin American patients with gastric cancer

    ecancermedicalscience, Vol. 16

  3. Clinical nutrition as part of the treatment pathway of pancreatic cancer patients: an expert consensus

    Clinical and Translational Oncology, Vol. 24, Núm. 1, pp. 112-126

  4. Cyclooxygenase 2 Effector Genes as Potential Inflammation-Related Biomarkers for Colorectal Cancer Circulating Tumor Cells Detection by Liquid Biopsy

    Frontiers in Pharmacology, Vol. 12

  5. Detection of Early-Stage Pancreatic Ductal Adenocarcinoma from Blood Samples: Results of a Multiplex Biomarker Signature Validation Study

    Clinical and Translational Gastroenterology, Vol. 13, Núm. 3, pp. E00468

  6. Disinfection By-Products in Drinking Water and Bladder Cancer: Evaluation of Risk Modification by Common Genetic Polymorphisms in Two Case-Control Studies

    Environmental health perspectives, Vol. 130, Núm. 5, pp. 57006

  7. Erratum: Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation (Oncotarget. (2020) 11 (2137–2140) DOI: 10.18632/oncotarget.27598)

    Oncotarget

  8. Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments

    European Journal of Cancer, Vol. 166, pp. 229-239

  9. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma

    Gut, Vol. 72, Núm. 2, pp. 345-359

  10. Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature

    Frontiers in Pharmacology, Vol. 13

  11. Precision Medicine: UGT1A1 Genotyping to Better Manage Irinotecan-Induced Toxicity

    JCO oncology practice, Vol. 18, Núm. 4, pp. 278-280

  12. Prognostic value of circulating endothelial cells in glioblastoma patients: A pilot study

    Future Science OA, Vol. 8, Núm. 5

  13. SNAI1-expressing fibroblasts and derived-extracellular matrix as mediators of drug resistance in colorectal cancer patients

    Toxicology and Applied Pharmacology, Vol. 450

  14. SNAI1-expressing fibroblasts and derived-extracellular matrix as mediators of drug resistance in colorectal cancer patients

    Toxicology and Applied Pharmacology, Vol. 450